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Disruption of the balanced modulation of reversible tyrosine phosphorylation has been implicated in the etiology
of various human cancers, including breast cancer. Protein Tyrosine Phosphatase N23 (PTPN23) resides in
chromosomal region 3p21.3, which is hemizygously or homozygously lost in some breast cancer patients. In a loss-
of-function PTPome screen, our laboratory identified PTPN23 as a suppressor of cell motility and invasion in
mammary epithelial and breast cancer cells. Now, our TCGA (The Cancer Genome Atlas) database analyses illus-
trate a correlation between low PTPN23 expression and poor survival in breast cancers of various subtypes.
Therefore, we investigated the tumor-suppressive function of PTPN23 in an orthotopic transplantation mouse
model. Suppression of PTPN23 in Comma 1Dβ cells induced breast tumors within 56 wk. In PTPN23-depleted
tumors, we detected hyperphosphorylation of the autophosphorylation site tyrosine in the SRC family kinase (SFK)
FYN as well as Tyr142 in β-catenin. We validated the underlying mechanism of PTPN23 function in breast tu-
morigenesis as that of a key phosphatase that normally suppresses the activity of FYN in two different models. We
demonstrated that tumor outgrowth from PTPN23-deficient BT474 cells was suppressed in a xenograft model in
vivo upon treatment with AZD0530, an SFK inhibitor. Furthermore, double knockout of FYN and PTPN23 via
CRISPR/CAS9 also attenuated tumor outgrowth from PTPN23 knockout Cal51 cells. Overall, this mechanistic
analysis of the tumor-suppressive function of PTPN23 in breast cancer supports the identification of FYN as a
therapeutic target for breast tumors with heterozygous or homozygous loss of PTPN23.
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The dynamic regulation of phosphorylation of tyrosyl
residues in proteins is maintained by the synchronized
and complementary activity of two enzyme families: pro-
tein tyrosine kinases (PTKs) and protein tyrosine phos-
phatases (PTPs). Disturbance of their functions disrupts
the balance of reversible tyrosine phosphorylation, which
impacts the normal patterns of intercellular and intracel-
lular signals and has been implicated in the etiology of
various human diseases, including cancer. Progress in un-
derstanding of the functions of PTKs in cancer has result-
ed in the development of novel therapeutics that target
specific changes in protein tyrosine phosphorylation-
dependent signaling that drive cancer etiology (Hunter
2009; Sliwkowski and Mellman 2013). In contrast, the
therapeutic potential of the PTPs has yet to be exploited
fully. Chromosomal aberrations, copy number variations,
and mutations have also been characterized in several
PTP genes in human cancer; in fact, now there are several
examples of PTPs as tumor suppressors or the products of
oncogenes (Alonso et al. 2004; Ostman et al. 2006; Julien
et al. 2011; Zhao et al. 2015). Nevertheless, the mechanis-
tic definition of the function of the majority of individual
PTPs remains to be established.
Breast cancer, which is the most prevalent malignancy
in women, is a heterogeneous disease that can be catego-
rized into five subtypes based on expression of particular
markers. They are luminal A and B (which are hormone
receptor-positive [estrogen and progesterone receptors]),
Corresponding author: tonks@cshl.edu
Article published online ahead of print. Article and publication date are
online at http://www.genesdev.org/cgi/doi/10.1101/gad.304261.117.
© 2017 Zhang et al. This article is distributed exclusively by Cold Spring
Harbor Laboratory Press for the first six months after the full-issue publica-
tion date (see http://genesdev.cshlp.org/site/misc/terms.xhtml). After six
months, it is availableunder aCreativeCommonsLicense (Attribution-Non-
Commercial 4.0 International), as described at http://creativecommons.org/
licenses/by-nc/4.0/.
GENES & DEVELOPMENT 31:1–19 Published by Cold Spring Harbor Laboratory Press; ISSN 0890-9369/17; www.genesdev.org 1
 Cold Spring Harbor Laboratory Press on November 3, 2017 - Published by genesdev.cshlp.orgDownloaded from 
HER2-positive (which are defined by high levels of the
HER2 PTK and are hormone receptor-negative), triple-
negative (which is both HER2-negative and hormone
receptor-negative and has also been classified as basal-
like), and normal-like (which is similar to luminal cancer,
being hormone receptor-positive but HER2-negative).
Currently, prognosis and therapeutic strategy vary for
each subtype. A variety of drugs that target HER2 have
been developed, including antibodies such as herceptin/
trastuzumab, antibody conjugates such as T-DM1/
Kadcyla, and small-molecule drugs such as lapatinib.
Although these target the cancer cell with specificity,
there remain problems of resistance, both intrinsic and ac-
quired, that limit the effectiveness of such therapies. In
contrast, triple-negative breast cancer (TNBC), which is
aggressive and characterized by poor prognosis (Rakha
et al. 2008), is treated with combinations of surgery, radi-
ation, and chemotherapies. It has been reported that there
are distinct tyrosine phosphorylation-dependent signa-
tures associated with basal breast cancer cells, in particu-
lar featuring the SRC family of PTKs (Hochgrafe et al.
2010). Nevertheless, these remain to be exploited for
targeted therapy, and further insights into the signaling
changes associated with the various breast cancer sub-
types are required.
In order to understand the potential therapeutic signifi-
cance of any alterations in tyrosine phosphorylation asso-
ciated with breast cancer, it is essential to establish the
contribution of both PTKs and PTPs to such changes.
Some progress has been made characterizing the function
of particular PTPs in breast cancer models. Considering
the conventional oncogenic function of PTKs and prompt-
ed by their opposing enzymatic function, the PTPs have
commonly been considered tumor-suppressive. Studies
in cell and animalmodels have implicated PTPRE, PTPRJ,
and PTPN13 in the development of breast cancer (Freiss
and Vignon 2004). The expression of PTPRG is down-reg-
ulated in breast tumors (Zheng et al. 2000). Inmechanistic
studies, PTPRO (Yu et al. 2012), PTPN9 (Yuan et al. 2010),
and PTPN13 (Zhu et al. 2008) have been shown to antag-
onize HER2 signaling via direct dephosphorylation in sev-
eral models of mammary carcinogenesis. Nevertheless,
some PTPs may also act as positive regulators in the
etiology of particular breast cancer subtypes. PTPRA is
overexpressed in ∼30% of primary human breast cancers,
with low tumor grade (Ardini et al. 2000), whereas PRL-3
(Radke et al. 2006) and LAR (Levea et al. 2000) are elevated
in metastatic breast cancer. PTPRE was found to play an
important role in HER2-mediated transformation as an
activator of SRC (Gil-Henn and Elson 2003). SHP2 also
has an oncogenic function in ERK activation inHER2-pos-
itive breast cancer (Bentires-Alj et al. 2006). However, the
function of some PTPs may vary according to the context
and stage of breast cancer development. For example,
PTPN12 has been identified as a tumor suppressor that
is frequently altered in TNBC,with effects onmultiple ty-
rosine phosphorylation-dependent signaling pathways
(Sun et al. 2011). In contrast, PTPN12 has also been impli-
cated in regulating levels of reactive oxygen species, there-
by promoting resistance to oxidative stress and favoring
tumorigenesis. It was reported that deletion of PTPN12
in human and mouse breast tumor cells decreased tumor-
igenic and metastatic potential in vivo, consistent with
PTPN12 itself being a therapeutic target in certain con-
texts (Harris et al. 2014).
In this study, we focused on PTPN23, which is a ubiqui-
tously expressed classical PTP composed of five domains
(Gingras et al. 2009a; Bissig and Gruenberg 2014). The
BRO1-like and V domains are important in ESCRT (endo-
somal sorting complexes required for transport) sorting of
several cell surface receptors, such as EGFR and integrin
(Ali et al. 2013; Kharitidi et al. 2015). The gene encoding
PTPN23 resides on chromosome 3p21, a region that is
frequently homozygously or hemizygously deleted in
various human tumors, also consistent with a tumor-
suppressive function (Senchenko et al. 2004; Angeloni
2007). The observation that the catalytic activity of
PTP-TD14 (the rat PTPN23 ortholog) is required to sup-
press RAS-mediated transformation of fibroblasts in soft
agar assay (Cao et al. 1998) emphasized the importance
of the C-terminal catalytic domain in its tumor suppres-
sor function. In addition, suppression of PTPN23 has
also been implicated in miR-142-3p-mediated increases
in soft agar colony formation by a human testicular
germ cell tumor cell line, whereas overexpression of
PTPN23 impedes xenograft growth of testicular germ
cell tumors in vivo (Tanaka et al. 2013). Furthermore,
in a transgenic mouse study, hemizygous deletion of
PTPN23 results in sporadic lung adenoma and B-cell lym-
phoma and promotes the establishment and progression
of Myc-driven lymphoma (Manteghi et al. 2016). In the
same study, it was reported that loss of PTPN23 in pa-
tients coincided with poor survival (Manteghi et al. 2016).
Our laboratory performed RNAi-mediated loss-of-func-
tion screens to test the effects of suppressing systemati-
cally the expression of PTP family members in three-
dimensional cell culture models. We identified several
PTPs as novel negative and positive regulators of HER2
signaling in the control of cell polarity, migration, and in-
vasion (Lin et al. 2011; Ramesh et al. 2015). Interestingly,
only PTPN23 was shown to inhibit mammary epithelial
cell motility and invasion in aHER2-independentmanner
by impairing the integrity of adheren junctions through
regulating the phosphorylation status of E-cadherin and
β-catenin (Lin et al. 2011). However, the extent to which
PTPN23 is tumor-suppressive in breast oncogenesis and
the mechanism by which it may exert such a function
are still unknown.
Here we report a loss-of-function study in which
PTPN23 was suppressed in transplantation and xenograft
mouse models to investigate a potential tumor-suppres-
sive role in breast tumorigenesis. We established a
mammary gland orthotopic transplantation model with
PTPN23-deficient Comma 1Dβ (CD) cells and observed
the incidence of basal-like breast tumors in PTPN23-defi-
cient animals. Importantly, we observed that PTPN23
recognized FYN as a physiological substrate, functioning
as a negative regulator of FYN activity in vitro and in
vivo. We demonstrated that tumorigenesis induced by
loss of PTPN23 in xenograft models was abated either
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by treatment with AZD0530, an SRC family kinase (SFK)-
specific inhibitor, or by cosuppression of PTPN23 and
FYN by CRISPR–CAS9 gene editing. Overall, our study
links the tumor-suppressive function of PTPN23 in breast
tumorigenesis to regulation of FYN phosphorylation and
activity, suggesting that FYN may be a therapeutic target
for breast cancer defined by hemizygous or homozygous
loss of PTPN23.
Results
Expression of PTPN23was down-regulated and positively
correlated with overall survival rate in breast cancer
patients
We analyzed data from 1069 breast cancer patients in
TCGA (TheCancerGenomeAtlas) to investigatewhether
there was a relationship between PTPN23 expression and
overall survival rate. The data indicated that expression of
PTPN23was positively correlated with overall survival in
breast cancer patients (Fig. 1A). In contrast, expression of
PTPRG, the only other classical PTP gene also localized
in chromosome 3 (Andersen et al. 2004), displayed no sig-
nificant correlation with overall survival ratio in breast
cancer patients (Fig. 1B). To examine further the patholog-
ical significance of PTPN23 expression in breast cancer
occurrence, we performed immunohistochemistry (IHC)
stainingwith antibodies against PTPN23. Two breast can-
cer tissue microarrays (TMAs), including normal breast
cores as controls (TMA US Biomax, Inc.), were stained
and scored for positive staining (Fig. 1C). Consistent
with clinical correlation,we observed in the first tissue ar-
ray a significant down-regulation of PTPN23 expression
in breast cancers (n = 100) compared with normal breast
core tissues (n = 10, P < 0.0001) (Fig. 1D), regardless of
their tumor stages (stage I [n = 5], stage II [n = 74], and stage
III [n = 21]) (Fig. 1E). More importantly, TNBC patients
in the second tissue array had the lowest PTPN23 expres-
sion among all receptor status subgroups (ER+ [n = 4], PR+
[n = 3], HER2+ [n = 15], and TNBC [n = 33]; P = 0.0017),
suggesting that deletion or suppression of PTPN23 was a
potential risk factor for TNBC occurrence and progression
(Fig. 1F). Overall, clinical analyses from TCGA database
andTMArevealed that attenuation of PTPN23 expression
in breast cancer, especially TNBC, was correlated with
poor long-term survival rate.
Suppression of PTPN23 in CD cells promoted tumor
formation in a BALB/c orthotopic transplantation model
Since the homozygous deletion of PTPN23 results in
embryonic lethality in a transgenicmousemodel (Gingras
et al. 2009a), we took advantage of an orthotopicmamma-
ry gland transplantation model using CD cells to investi-
gate the tumor-suppressive function of PTPN23 in breast
tumorigenesis. CD cells, a mammary gland epithelial pro-
genitor cell line derived from mammary gland of mid-
phase pregnant BALB/c mice, are able to differentiate
into cells with both luminal and basal epithelial cell
properties. As a consequence of their immortal nature
and pluripotency, CD cells are used widely in studies of
mammary gland development and breast cancer tumori-
genesis (Danielson et al. 1984; Ibarra et al. 2007). The
experimental scheme is summarized in Figure 2A. First,
we selected two effective shRNAs (shPtpn23 #2913 and
#3971) to suppress PTPN23 in CD cells (Fig. 2B) and
then injected these cells into cleared abdominal fat pads
(fourth pair) of 3-wk-old female BALB/c mice (12 mice
per group). Although Ptpn23 knockdown did not alter
CD cell proliferation in a CellTiter-Glo viability assay
(Supplemental Fig. S1A), we did observe the onset of
breast tumors in Ptpn23 knockdown cohorts from week
20 post-transplantation. In the tumor-free curve (Fig.
2C), seven of 12 mice in the shPtpn23 #2713 cohort
and eight of 12 in the shPtpn23 #3971 cohort developed
palpable breast tumors in one or both transplanted fat
pads within 56 wk, whereas the shLuc (shRNA against
firefly luciferase) cohort remained tumor-free (as assessed
by palpation). All breast tumors grew at a high rate
in vivo, and mice were euthanized above a tumor burden
of d≥ 20mm. In fact, six of 12 littermates in the shPtpn23
#2713 cohort and seven of 12 in the shPtpn23 #3971 co-
hort (Fig. 2D) were euthanized due to aggressive tumor
progression by the end of 56 wk.
Histologically, we categorized CD cell-derived breast
tumors from 10 mice in the shPtpn23 #2713 cohort and
nine in the shPtpn23 #3971 cohort into two major sub-
types (Supplemental Fig. S1B). One was adenosquamous
carcinoma and the other was anaplastic carcinoma (Fig.
2F), both of which are basal-like breast tumor subtypes.
Additionally, we observed lung macrometastasis in one
littermate from each shPtpn23 cohort. The shRNA
cassettes coexpress GFP; using fluorescence microscopy,
we detected GFP in shPtpn23 tumor sections but not
in normal mammary glands (Supplemental Fig. S1C),
confirming that the tumors were derived from PTPN23-
deficient CD cells. In addition, we demonstrated that
PTPN23 was efficiently suppressed in shPtpn23 CD cells
during tumor development in vivousing IHCwith fluores-
cence detection (Supplemental Fig. S1D). Approximately
40% of cells were PTPN23-positive in normal (44%) and
control shLuc (42%) mammary glands, whereas only
12% were positive in shPtpn23 tumors (Supplemental
Fig. S1E). Expression of PTPN23 in shPtpn23 tumor ly-
sates was as low as that observed in shPtpn23 CD cells,
suggesting sustained knockdown of Ptpn23 during tumor-
igenesis (Supplemental Fig. S1F). In conclusion, this is
consistent with a tumor suppressor function of PTPN23,
with suppression of PTPN23 promoting CD cells to
develop into basal-like breast tumors in orthotopically
transplanted BALB/c mice.
Loss of PTPN23 sustained FYN activity, with
concomitant phosphorylation of β-catenin on Tyr142
in CD cells
Our previous study indicated that depletion of PTPN23
elevated the activity of SFKs as well as tyrosine phosphor-
ylation of β-catenin on Tyr142 (Lin et al. 2011). Further-
more, in a loss-of-function screen of classical PTPs,
Mechanism of PTPN23 tumor suppressor function
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Figure 1. Expression of PTPN23was down-regulated and correlated positivelywith overall survival rate in breast cancer patients. (A,B) A
data set of 1069 breast cancer cases was extracted from TCGA database. PTPN23 and PTPRG expression was stratified as high versus low
against median expression, and overall survival probability between these two subgroups was plotted. (A) PTPN23. (B) PTPRG. The P-val-
ue was calculated with two-tailed log-rank (Mantel-Cox) test. (C ) Representative IHC staining of PTPN23 (brown) in normal adjacent tis-
sue (top panel) and breast tumor specimens classified by the TNMstaging system (middle panel) as well as receptor status (bottom panel).
Bar, 200 µm. (D) Expression of PTPN23 in normal adjacent tissue (n = 10) and breast tumor specimens (n = 100) was scored by Aperio
ImageScope software and plotted as mean + SD. (E) Expression of PTPN23 in individual TNM tumor stage I (n = 5), stage II (n = 74), and
stage III (n = 21) subgroups was also plotted as mean ± SD, with that of normal breast core tissues (n = 10) as control. (F ) Expression of
PTPN23 in ER+ (n = 4), PR+ (n = 3), HER2+ (n = 15), and TNBC (n = 33) was plotted as mean ± SD, with that of normal breast core tissues
(n = 10) as control. (∗) P < 0.05, unpaired two-tailed Student’s t-test; (∗∗) P < 0.01, unpaired two-tailed Student’s t-test.
Zhang et al.
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Figure 2. Suppression of PTPN23 inCD cells promoted breast tumor formation in a BALB/cmouse orthotopic transplantationmodel. (A)
Schematic summary of the use of CD cells in a mammary gland orthotopic transplantation model in BALB/c mice. (B) Total cells lysates
from Ptpn23 knockdown (shPtpn23 #2913 and #3971) and control (shLuc) CD cell lines were immunoblotted for PTPN23 and β-actin. (C )
All BALB/cmiceweremonitored for any palpable breast tumor two times aweek for 56wk. The percentage of tumor-free animals in three
individual cohorts (shLuc, shPtpn23 #2913, and shPtpn23 #3971) was plotted against time. (∗∗) P < 0.01, two-tailed log-rank (Mantel-Cox)
test. (D) Mouse mortality, either direct deceased or by euthanasia with a heavy tumor burden (>4 cm3), was documented in Kaplan-Meier
survival curves for all three cohorts (shLuc, shPtpn23 #2913, and shPtpn23 #3971). (∗∗) P < 0.01, two-tailed log-rank (Mantel-Cox) test. (E)
Representative animal necropsy images fromeach cohort, showingmammary glands in theCD shLuc cohort and breast tumors (red circle)
in the CD shPtpn23 #2913 and hPtpn23 #3971 cohorts. Bar, 2 cm. (F ) Representative H&E staining images for repopulated mammary
glands and twomajor breast tumor subtypes derived fromCD cells in BALB/cmice. (Panel a) Mammary gland reconstituted by CD shLuc
cells. (Panel b) Atypical hyperplasia and high-grade MIN (mammary intraepithelial neoplasis) developed from CD shPtpn23 #2913 cells.
(Panel c) Adenosquamous carcinoma developed from CD shPtpn23 #2913 cells. (Panel d ) Anaplastic carcinoma with traces of stroma de-
veloped from CD shPtpn23 #3971 cells. Bar, 100 µm.
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depletion of which led to elevated Tyr142 phosphoryla-
tion in β-catenin, we also identified PTPN23 as one of
the top hits (Supplemental Fig. S2A,B). In order to investi-
gate the underlying mechanism by which suppression
of PTPN23 in CD cells led to breast oncogenesis in the
transplantation model, we tested first whether the same
regulation would occur in vivo. Therefore, we performed
IHC staining of tissue samples with specific antibodies
to demonstrate the phosphorylation status of β-catenin
on Tyr142 (Fig. 3A) and the Tyr autophosporylation site
in the activation loop of SFKs (Fig. 3B). The percentage
of positive staining of pTyr142 (Supplemental Fig. S2C)
and total β-catenin (data not shown) was scored and calcu-
lated for each sample. As expected, we detected a higher
percentage of cells that stained positive for pTyr142
β-catenin with strong intensity in shPtpn23 tumors
(66%) compared with shLuc mammary glands (6%) or
normal mammary glands (5%). Consistently, the ratio of
pTyr142 over total β-catenin staining in shPtpn23 tumors
(66%) was significantly higher than in shLuc (14%) and
normal (15%) mammary glands (Supplemental Fig. S2D).
Consistent with the elevated β-catenin phosphorylation
on Tyr142, we observed that a higher percentage of cells
stained positive for the pTyr autophosphorylation site in
Figure 3. Loss of PTPN23 sustained FYN
activity, with concomitant phosphoryla-
tion of β-catenin on Tyr142 in CD cells.
(A) IHC staining of pTyr142 β-catenin (left)
and β-catenin (right) of a mammary gland
section following CD shLuc cell transplan-
tation (top panel) and a breast tumor section
following CD shPtpn23 #2913 cell trans-
plantation (bottom panel). Nuclei were
also stained (blue). Bar in 20-fold magnifica-
tion images, 50 µm. (B) IHC staining of the
autophosphorylation site pTyr of SFK (ac-
tive) from a mammary gland section with
CD shLuc cell transplantation (top panel)
and a breast tumor section with CD
shPtpn23 #2913 cell transplantation (bot-
tom panel). Nuclei were also stained
(blue). Bar in 20-fold magnification images,
50 µm. (C ) Mammary glands from both
untransplanted and CD shLuc cohorts as
well as tumor tissues from both shPtpn23
#2913 and shPtpn23 #3971 cohorts were
frozen and lysed. Four replicates of tissue ly-
sates (M1 to M4) from each group (untrans-
planted normal mammary glands [Cont.
MG], shLuc, shPtpn23 #2913, and shPtpn23
#3971) were immunoblotted with antibod-
ies against PTPN23 to confirm the knock-
down efficiency. Tissue lysates were also
immunoblotted against pTyr142 and total
β-catenin and pTyr-SFK and total FYN.
HEK293T cells were transiently transfected
with empty vector (EV) (D,E) and vectors
that express wide-type or Y420F or K299M
mutant FYN (D). (E) A CD cell line stably
expressing ectopic FYN was also estab-
lished. All cell lysates were harvested to
probe for pTyr142 and total β-catenin and
pTyr-SFK (pY420 FYN) and total FYN,
with β-actin as a loading control. (F ) Paren-
tal, shLuc, shPtpnN23 #2913, and shPtpn23
#3971 CD cell lines were stimulated with
complete growth medium for 30 min after
overnight serum starvation. PTPN23,
pTyr142, and total β-catenin were probed
by immunoblotting. FYN and SRC were
immunoprecipitated followed by immuno-
blotting with pTyr-SFK antibody to check
the activation status of FYN and SRC in
all four CD cells.
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SFKs in shPtpn23 tumors (51%) than in shLuc (18%) or
normal (13%) mammary glands (Supplemental Fig. S2E).
To confirm the result, tissue lysates from mammary
glands (shLuc), breast tumors (shPtpn23 #2913 and
#3971), and untransplanted normal mammary glands
were collected and subjected to immunoblotting. As
expected, we detected increased β-catenin and SFK phos-
phorylation in tumor lysates compared with mammary
gland controls (Fig. 3C).
As functional kinases, activated SFKs are able to convey
signals through substrate phosphorylation; however, the
question remained which SFK was important in this con-
text? The Dunach laboratory (Piedra et al. 2003) reported
that increased phosphorylation of Tyr142 in β-catenin in
epithelial cells was accompanied by the activation of
FYN kinase. Furthermore, FYNwas shown to phosphory-
late β-catenin on Tyr142 in vitro (Piedra et al. 2003).
Therefore, we investigated whether Tyr142 of β-catenin
could also be phosphorylated by FYN in CD cells.We con-
firmed the expression of FYN in CD cells (Supplemental
Fig. S2F) and demonstrated that only wild-type, but not
Y420F (kinase-inactivated) or K299M (kinase-dead) mu-
tants of, FYN could phosphorylate β-catenin on Tyr142
in 293T cells (Fig. 3D). Finally, we detected the robust
phosphorylation of β-catenin on Tyr142 in CD cells in
which FYN was stably expressed (Fig. 3E). These data
indicate that Tyr142 of β-catenin is a substrate of FYN.
To provide further evidence that the activation of FYN
was enhanced in CD cells following suppression of
PTPN23, we serum-starved shLuc, shPtpn23 #2913,
shPtpn23 #3971, and parental CD cells overnight and
restimulated them in complete growth medium for
30 min. FYN and SRC were immunoprecipitated from
the cell lysates, and activation of these two kinases was
examined. Compared with parental and shLuc CD cells,
we observed increased autophosphorylation of FYN
Tyr420 in both shPtpn23 #2913 and shPtpn23 #3971 CD
cells. However, autophosphorylation of Tyr416 in SRC
remained unchanged among these samples (Fig. 3F). Inter-
estingly, the phosphorylation status of β-catenin on
Tyr142 was also dramatically elevated upon PTPN23 sup-
pression (Fig. 3F). Taken together, these data indicate both
in vivo and in vitro that suppression of PTPN23 in CD
cells enhanced FYN autophosphorylation and activation,
with a concomitant increase in phosphorylation of β-cate-
nin on Tyr142.
PTPN23 dephosphorylated FYN on Tyr420
In order to validate FYN as a bona fide substrate of
PTPN23, we first performed in vitro substrate trapping
experiments in CD cells. This approach, which has served
as an important tool to identify putative PTP substrates,
is based on stabilization of a PTP–substrate complex fol-
lowing mutation of an invariant Asp residue in the WPD
loop to Ala (WPE loop in PTPN23) or mutation of the nu-
cleophilic Cys to Ser in the PTP signature motif (Flint
et al. 1997). We introduced both Flag-tagged C1392S and
E1357Amutants of PTPN23 in CD cells to compare their
interaction with FYN with that of wild-type PTPN23.
Analysis by coimmunoprecipitation illustrated greater
complex formation between these PTPN23 mutants and
FYN compared with the wild-type phosphatase (Fig. 4A).
We repeated the substrate-trapping experiment in CD
cells and assessed the phosphorylation status of FYN
with antibodies against either the autophosphorylation
site (pTyr420 FYN) or the inhibitory C-terminal pTyr
phosphorylation site (pTyr531 FYN). In agreement with
what we observed in tissue samples (Fig. 3B), the portion
of FYN that coimmunoprecipitated with the PTPN23
CS mutant was highly phosphorylated on Tyr420 but
not on Tyr531 (Fig. 4B). Importantly, Y420F, but not
the Y531F mutant of FYN, did not autophosphorylate or
associatewith the PTPN23CSmutant (Fig. 4C). To exam-
ine substrate selectivity, we repeated these assays using
PTPN23 CS together with two other SFK members, SRC
and YES, in CD cells. Unlike FYN, we detected no associ-
ation between the PTPN23 CS mutant and these two
kinases even with their activating tyrosine residue phos-
phorylated (Supplemental Fig. S3A–C).
To consolidate the substrate-trapping data, we investi-
gated whether FYN was a direct substrate of PTPN23 in
a dephosphorylation assay in vitro. We enriched Y531F
FYN as substrate by immunoprecipitation following tran-
sient expression in CD cells. Following incubation of the
wild-type PTPN23 catalytic domainwith Y531F FYN, the
extent of phosphorylation of pTyr420 in FYN was dimin-
ished, whereas incubation with C1392S mutant PTPN23
did not result in dephosphorylation (Fig. 4D). Sequence
alignments of all classical PTPs revealed that PTPN23
harbors three amino acid residue alterations in its catalyt-
ic motif (His1223, Glu1357, and Ser1394) compared with
the normal consensus. In order to test whether any of the
three alterations had an impact on enzymatic activity, we
purified the PTPN23 catalytic domain with site-directed
mutations at each of the three residues (H1223Y, E1357D,
and S1394A) as well as a triple-mutant form (H1223Y/
E1357D/S1394A) to convert to the consensus sequence.
Although the three single-mutant forms of the PTPN23
catalytic domain (H1223Y, E1357D, and S1394A) dephos-
phorylated pTyr 420 of FYN comparably with the wild-
type PTPN23 catalytic domain, the activity of the triple
mutant (H1223Y/E1357D/S1394A) was elevated (Fig.
4D). In summary, the data revealed FYN as a bona fide
substrate of PTPN23, and its activity may be inhibited
by PTPN23 through direct dephosphorylation of Tyr420
in the activation loop.
Treatment of AZD0530, a specific SFK inhibitor, offsets
BT474 breast tumor progression induced by PTPN23
suppression
In parallel with the transplantation model, we also inves-
tigated the function of PTPN23 on tumor progression in a
SCID/Beige xenograft model with BT474 cells, a HER2+
breast cancer cell line. The BT474 cells were engineered
to express a luciferase cassette to permit examination of
tumor development via living bioluminescence imaging.
Consistent with the results of our transplantation model,
suppression of PTPN23 in BT474 cells via two individual
Mechanism of PTPN23 tumor suppressor function
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shRNAs accelerated growth of breast tumors, as mea-
sured by size and net weight, in this xenograftmodel (Sup-
plemental Fig. S4A–E), consistent with a general tumor-
suppressive role for PTPN23 in different breast cancer
subtypes.
Considering that expression of PTPN23 was down-
regulated in a broad array of breast cancers (Fig. 1) and
that PTPN23 negatively modulated FYN kinase activity
by dephosphorylation of Tyr420 in vitro (Fig. 4), we tested
whether this mechanism also explained the tumor-sup-
pressive role of PTPN23 in breast cancer models. We se-
lected an SFK-specific inhibitor, AZD0530 (Saracatinib),
to inhibit the kinase activity of FYN in vivo (Hennequin
et al. 2006). If PTPN23 exerted its tumor suppressor
function through the regulation of FYN activity in vivo,
we anticipated that treatment with AZD0530 may allevi-
ate breast tumor progression in the xenograft model. As
shown in Figure 5A, tyrosine phosphorylation of SFK in
the activation loop was elevated in PTPN23-deficient
BT474 cells, and this phosphorylation was abrogated
upon treatment with 5 µM AZD0530, confirming the in-
hibitory effect of this compound. We injected shPTPN23
#1058 and shCont BT474 cells bilaterally into the left
and right abdominal mammary gland fat pads (Fig. 5C,
ventral view) of 8-wk-old female SCID/Beige mice. Two
weeks after injection, 25 mg/kg AZD0530 was adminis-
tered orally every 3 d for 6 wk to one cohort of animals
(n = 8), whereas vehicle control (5% DMSO diluted in
saline) was administered to the other cohort (n = 9)
(Fig. 5B). Wemonitored body weight and calibrated tumor
size of each animal every 3 d for 6 wk. There was no
detectable gain or loss in body weight between the two
cohorts (Fig. 5C); however, compared with vehicle,
AZD0530 treatment did significantly delay the tumor
progression of PTPN23-deficient BT474 cells (54-d treat-
ment: 270 mm3 vs. 100 mm3) (Fig. 5D). After euthanasia,
all of the tumors were dissected and measured ex vivo.
Compared with the shPTPN23 vehicle cohort, both tu-
mor volume and weight from the shPTPN23-AZD0530
cohort were reduced to levels observed in the shCont
vehicle cohort (Fig. 5E,F). Furthermore, representative
bioluminescence images of one littermate from each
treatment group on day 14 and day 46 illustrated the
delayed tumor growth from the shPTPN23 AZD0530
Figure 4. PTPN23 dephosphorylated FYN on
Tyr420. (A) CD cells were transiently transfected
with mammalian expression vectors for both FYN
and Flag-tagged wild-type (3xFlag N23 wild-type) or
substrate-trapping mutant (3xFlag N23 C1392S and
E1357A) forms of PTPN23. Cell lysates were harvest-
ed and immunoprecipitated with Flag antibody-con-
jugated magnetic beads. The interactions of FYN
with wild-type, C1392S, or E1357A PTPN23 were as-
sessed by immunoblotting with the appropriate anti-
bodies. β-Actin was probed as the loading control. (B)
CD cells were transiently transfected with the indi-
cated vectors, lysed, and immunoprecipitated with
Flag antibody-conjugated magnetic beads. The im-
munoprecipitates and 10% input lysates were probed
with the indicated antibodies. (C ) Potential PTPN23
dephosphorylation sites were investigated using
kinase-impaired (Y420F) and constitutively active
(Y531F) mutant forms of FYN. CD cells transiently
transfected with vectors expressing wild-type,
Y420F, and Y531F FYN in combination with
PTPN23 wild-type and C1392S vectors, as indicated,
were lysed and immunoprecipitated with Flag anti-
body-conjugated magnetic beads. The immunopre-
cipitates and 10% input cell lysates were probed
with the indicated antibodies. β-Actin was probed as
the loading control. (D) Y531F FYN was expressed
in CD cells and immunoprecipitated with FYN anti-
body. Equal amounts of the immunoprecipitate were
incubated with a panel of purified PTPN23 catalytic
domains at the indicated amounts for 30 min at 30°
C, including the wild-type and five mutant forms of
PTPN23 (C1392S, H1223Y, E1357D, S1394A
PTPN23, and C1392S/H1223Y/E1357D PTPN23).
The reaction was terminated by addition of sample
buffer, and dephosphorylation of pTyr420 in FYN
was assessed by immunoblotting with the indicated
antibodies.
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cohort (Fig. 5G). The dissection image of the same pair of
mice on day 60 also contrasted the actual tumor size, sug-
gesting that SFK inhibition offset the effect of PTPN23
suppression on tumor progression in BT474 xenografts
(Fig. 5H).
Finally, we harvested tumor samples from all litter-
mates in both treatment groups for biochemical exami-
nation. First, we randomly paired tumor tissues from
three mice treated with vehicle (M1, M2, and M3) and
three mice treated with AZD0530 (M4, M5, and M6), im-
munoprecipitated FYN, and then compared the extent of
phosphorylation of Tyr420 by immunoblotting. In the ve-
hicle treatment group, shPTPN23 tumors showed a high-
er phosphorylation status of Tyr420 in FYN than in the
shCont cohort; however, FYN Tyr420 autophosphoryla-
tion was abrogated in both shCont and shPTPN23 tumor
lysates following AZD0530 treatment (Fig. 5I; Supple-
mental Fig. S5A,B). Second, we performed IHC staining
for H&E (Supplemental Fig. S5C, left), PTPN23 Supple-
mental Fig. S5C, (middle), and SFK autophosphorylation
(Supplemental Fig. S5C, right) on all tumor slides and
scored for positive staining (Supplemental Fig. S5D,E).
Suppression of PTPN23 enhanced tyrosine phosphoryla-
tion of SFK; however, this increase was dramatically
inhibited following AZD0530 administration (Sup-
plemental Fig. S5C–E). In conclusion, the accelerated tu-
mor progression in the PTPN23-deficient BT474 cohort
was profoundly delayed upon AZD0530 treatment, con-
sistent with a driving role for up-regulated FYN kinase
activity.
Figure 5. Treatment with AZD0530, a specific SFK
inhibitor, attenuated BT474 breast tumor progression
induced by PTPN23 suppression. (A) Prior to the xe-
nograft experiment, inhibition of kinase activity by
AZD0530 as well as PTPN23 knockdown efficiency
were examined by immunoblotting with the indicat-
ed antibodies in BT474 cell lines (shCont and
shPTPN23 #1058). β-Actin was probed as the loading
control. (B) Schematic plan for the mammary gland
orthotopic xenograftmodel in SCID/Beigemice using
BT474 cells and treatment with AZD0530 (saracatib-
nib). (C ) shPTPN23 #1058 and shCont BT474 cells
(1.5 × 106 cells) were orthotopically injected into the
left and right abdominal mammary glands (ventral
view), respectively. Each animal was administrated
either vehicle or 25 mg/kg AZD0530. Body weight
was monitored in grams and plotted every 3 d after
14-d tumor onset. (n.s.) Not significant, two-tailed
log-rank (Mantel-Cox) test. (D) For each xenograft tu-
mor, the length and width were measured with cali-
pers (in millimeters) every 3 d before treatment. The
tumor volume was calculated in cubic millimeters
[volume = (width ×width × length)/2], and the mean
± SD was plotted for the vehicle-treated and 25 mg/
kg AZD0530-treated cohorts. (n.s.) Not significant;
(∗∗) P < 0.01, two-tailed log-rank (Mantel-Cox) test.
(E,F ) Each tumor in the four individual treatment sub-
groups was collected after euthanasia, with its length
and width calibrated in millimeters and its volume
calculated in cubic millimeters [volume = (width ×
width × length)/2]. (E) The mean ± SD of tumor vol-
ume for the four indicated subgroups was plotted.
Furthermore, the net weight of each tumor was mea-
sured in milligrams. (F ) The mean ± SD of tumor
weight for the four indicated subgroups was plotted.
(n.s.) Not significant; (∗∗) P < 0.01, two-tailed Mann-
Whitney test. (G) Bioluminescence in vivo imaging
was applied to show the effect of AZD0530 treat-
ment. Representative images were taken at the first
and last day of the treatment. (Right) BT474 shCont
cells. (Left) BT474 shPTPN23 #1058 cells. Biolumi-
nescence signals were quantitated by Living Image software. The intensity is represented by rainbow scale, ranging from 2000 to
60,000 counts. (H) Representative animal images showing the effect of AZD0530 treatment. (Right) BT474 shCont cells. (Left) BT474
shPTPN23 #1058 cells. Bar, 2 cm. (I ) Dissected tumor tissues from both vehicle-treated (M1, M2, and M3) and AZD0530-treated (M4,
M5, and M6) cohorts were frozen, lysed, and immunoblotted with the indicated antibodies to confirm the efficiency of PTPN23 knock-
down and AZD0530 inhibition. All tumor tissue lysates were also immunoprecipitated with FYN antibody followed by immunoblotting
with pTyr-SFK (pY420 FYN) antibody and reprobing of FYN (M1 and M4 are shown). β-Actin was probed as the loading control.
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Simultaneous targeting of both PTPN23 and FYN by
CRISPR–CAS9 attenuated breast tumorigenesis
induced by PTPN23 suppression alone
Although AZD0530 specifically targets SFKs, it shows lit-
tle selectivity among the family. To address whether FYN
was a primary target of AZD0530 in the above study, we
took advantage of the CRISPR–CAS9 system to target
simultaneously both PTPN23 and FYN in our xenograft
model (Fig. 6A). For this experiment, we selected Cal51,
a human TNBC (basal-like) cell line, because pathology
analysis of our previous transplantation model revealed
a basal-like tumor property following suppression of
PTPN23. Endogenous expression of PTPN23 and FYN
was detected in the Cal51 cell line (Supplemental Fig.
S6A). Small guide RNAs (sgRNAs) were generated to tar-
get the catalytic domains of PTPN23 (exon 22 [E22] and
exon 23 [E23]) and FYN (exon 13 [E13]) as well as AAVS1
as a negative control.
First, we established a Cal51_CAS9 cell line. After
sgRNA lentiviral particle infection, GFP/mCherry mark-
er sorting, and single clone selection, the knockout
efficiency of PTPN23 and FYN in Cal51_CAS9 cells was
confirmed by immunoblotting (Fig. 6B). Next, we per-
formed in vitro cell proliferation assays using an automat-
ed cell counter with six genetically modified Cal51 cell
lines over 2 wk. These cells were refreshed with growth
medium plus either vehicle or 2 µM AZD0530 every
other day. Both PTPN23 knockout E22 and E23 cell lines
proliferated faster than the CAS9 control (sgAAVS1) and
FYN knockout E13 from day 4, whereas growth of the
PTPN23 and FYN double-knockout cell line was slowed
to the same rate as the CAS9 control (Supplemental Fig.
S6B). Furthermore, treatment with 2 µM AZD0530 abol-
ished the outgrowth of PTPN23 knockout E22 and E23
cell lines, similar to the PTPN23/FYN double-knockout
phenotype (Supplemental Fig. S6C). In addition, we exam-
ined the tyrosine phosphorylation status of the activation
loop of SFKs in the presence and absence of AZD0530.
Whereas there was a clear elevation of SFK autophosphor-
ylation inCal51 cells upon loss of PTPN23, this autophos-
phorylation was blocked up to 48 h after the addition of
AZD0530 (Supplemental Fig. S6D,E).
Finally, in the xenograft study, we allowed 2 wk for tu-
mor onset after Cal51 cell injection (n = 8 for each cohort)
and then monitored tumor growth for the following 6 wk.
Consistent with the previous BT474 xenograft model, we
observed that tumors grew faster in PTPN23 knockout
xenograft groups than those in the CAS9 control group
(Fig. 6C), and codeletion of FYN in the PTPN23-deficient
background significantly slowed tumor progression (Fig.
6C). After euthanasia and necropsy, we measured tumor
volume and weight for xenografts from all littermates.
Consistently, the double knockout of both PTPN23 and
FYN profoundly reduced both tumor volume and weight
to a level similar to that of the CAS9 control and FYN
knockout E13 (Fig. 6D,E). These results are further sup-
ported by the tumor dissection images in Figure
6F. Taken together, studies fromCRISPR–CAS9-mediated
double-knockout Cal51 cells illustrated effects on tumor
progression in vivo similar to those observed following
treatment with AZD0530. However, the cleaner back-
ground to this new model ameliorates concerns regarding
off-target effects of the SFK inhibitor used in the previous
xenograft model.
Discussion
The PTPN23 gene maps to human chromosome 3p21.3, a
chromosome region with frequent loss of heterozygosity
and large homozygous deletions in various epithelial can-
cers, including breast cancer (Toyooka et al. 2000). Conse-
quently, it has been considered as a candidate tumor
suppressor gene. It is broadly expressed in various tissues,
particularly in epithelial cells (Gingras et al. 2009a). Sup-
pression of PTPN23 promoted cell motility and invasion
(Lin et al. 2011), whereas overexpression suppressed
RAS-mediated transformation of fibroblasts (Cao et al.
1998) and impaired growth of renal cancer cells (Gingras
et al. 2009b). Furthermore, the suppression of PTPN23
via miR-142-3p increases soft agar colony formation of a
human testicular germ cell tumor cell line (Tanaka et al.
2013). In animal models, insertion of a β-geo cassette
into the PTPN23 locus, which resulted in expression of a
catalytically inactive truncated PTPN23 fusion protein
containing only the BRO1-like domain, causes embryonic
lethality in transgenic mice (Gingras et al. 2009a), consis-
tent with an essential developmental function. Although
homozygous loss was embryonic-lethal, hemizygous loss
of PTPN23 resulted in cancer predisposition. For example,
crossing Ptpn23+/− mice into the Eμ-myc B-cell lympho-
ma model leads to accelerated onset of lymphoma and
reduced survival, consistent with PTPN23 exerting a tu-
mor-suppressive function in a haploinsufficient manner
(Manteghi, et al. 2016). In contrast, several studies have
used CRISPR screens or gene-trapping approaches that
have identified PTPN23 as an essential gene (Blomen
et al. 2015; Hart et al. 2015; Wang et al. 2015); for
example, in Raji cells, a B-cell-derived Burrkit’s lympho-
ma, PTPN23 is required for proliferation and survival in
this lymphoma, suggesting that it may be a point of vul-
nerability for the cancer (Wang et al. 2015). Such data re-
inforce the importance of recognizing PTPs as specific
regulators of signaling pathways that may exert distinct
positive or negative effects in different contexts.
There are precedents for individual PTPs serving as
proto-oncogenes or tumor suppressors in specific cancers,
depending on the modulation of particular cellular signal-
ing pathways and involving different cellular processes.
For example, SHP2, which is encoded by the Ptpn11
gene, was first identified as an oncogenic PTP because
somatic gain-of-function mutations in SHP2 cause exces-
sive activation of RAS–MAPK signaling and are associated
with increased risk of juvenile myelomonocytic leukemia
(JMML) and some solid tumors (Tartaglia et al. 2003,
2004; Mohi et al. 2005; Xu et al. 2005; Chan et al. 2009).
On the other hand, Ptpn11 is a tumor suppressor gene in
cartilage, in which loss of function is associated with
metachondromatosis through alterations in FGF-induced
Zhang et al.
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Figure 6. Simultaneous targeting of both PTPN23 and FYN by CRISPR–CAS9 attenuated breast tumorigenesis induced by PTPN23 sup-
pression alone. (A) Time line and schematic plan for the mammary gland orthotopic xenograft model using SCID/Beige mice and Cal51
cells after PTPN23 knockout, FYN knockout, and PTPN23/FYN double knockouts. (B) Prior to the xenograft experiment, the efficiency of
CRISPR/CAS9 ablation using sgRNA against E22 or E23 of PTPN23 (PTPN23 KO E22 and E23) and sgRNA against E13 of FYN (FYN KO
E13) was confirmed by immunoblotting with the indicated antibodies in Cal51 cell lines. An AAVS1 sgRNA expression cassette integrat-
ed into the Cal51_CAS9 cell line was also selected as a control. β-Actin was probed as the loading control. (C ) Four cohorts of mice (n = 8)
were orthotopically injected with 1.5 × 106 Cal51 cells into the abdominal mammary glands, as indicated (left/right from ventral view).
The length and width of each xenograft tumor were measured with calipers every 3 d after injection. The tumor volume was calculated
in cubic millimeters [volume = (width ×width × length)/2] and plotted for each of the indicated subgroups as the mean ± SD from day 21
post-xenograft. (∗∗) P < 0.01, two-tailed log-rank (Mantel-Cox) test. (D,E) Tumors from six subgroups were collected after animal euthana-
sia. (D) The mean ± SD of tumor volume for each of the six indicated subgroups was plotted. Furthermore, the net weight for each tumor
wasmeasured inmilligrams. (E) Themean ± SD of tumor weight for each of the six indicated subgroups was plotted. (n.s.) Not significant;
(∗∗) P < 0.01, two-tailedMann-Whitney test. (F ) Representative images of one xenograft animal from cohort 1 (panel a), cohort 2 (panel b),
cohort 3 (panel c), and cohort 4 (panel d ) illustrating the tumor in SCID/Beige mice. Bar, 2 cm.
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MAPK signaling (Yang et al. 2013). In addition, hepato-
cyte-specific ablation of the Ptpn11 gene in mice induced
spontaneous macroscopic adenomas with elevated in-
flammatory signaling through hyperphosphorylation and
activation of STAT3. Deletion of the Ptpn11 gene also
significantly enhanced hepatocellular carcinoma develop-
ment upon diethylnitrosamine induction, suggesting a tu-
mor-suppressive function of SHP2 (Bard-Chapeau et al.
2011). An additional example is PTP1B. The PTPN1
gene, which encodes PTP1B, is located at chromosome
20q13, which is a region that is frequently amplified in
breast cancer and associated with poor prognosis. In fact,
PTP1B plays a positive role in promoting signaling events
associated with HER2-induced breast tumorigenesis
(Tonks and Muthuswamy 2007). The mechanisms under-
lying this effect have been proposed to involve regulation
of the tyrosine phosphorylation of p62DOK and thereby
control over the levels of p120RASGAP (Julien et al.
2007) as well as regulation of nonmitochondrial oxygen
consumption to control tumor survival in hypoxia (Banh
et al. 2016). In contrast, ablation of PTP1B in p53-null
mice promoted lymphomagenesis and decreased survival
rates (Dube et al. 2005). Paradoxical effects of PTP1B in
tumor progression also occurred in different prostate can-
cer animal models. PTP1B has been linked with a tumor-
promoting function for migration and invasion in prostate
cancer, which is dependent on androgen receptor signal-
ing (Lessard et al. 2012), whereas coordinated loss of
PTP1B in PTEN-deficient mice caused an invasive pros-
tate cancer upon high-fat diet feeding due to elevated
PI3K–AKT signaling (Labbe et al. 2016). Finally, the
PRLs (phosphatase of regenerating liver) offer an intrigu-
ing example of a PTP that serves an oncogenic function
through a mechanism that does not involve the catalytic
activity of the enzyme; instead, it promotes tumor
growth by forming a heterodimer with members of the
CNNM family of magnesium transporters and regulating
levels of intracellular magnesium (Hardy et al. 2015).
In contrast, Prl-3 has also been identified as a p53-induc-
ible gene that can function positively or negatively in reg-
ulation of the cell cycle, depending on its level of
expression (Basak et al. 2008). In addition, PRL-1 was
shown to function as a suppressor of growth in transgenic
Drosophila through a mechanism that involved suppres-
sion of SRC function (Pagarigan et al. 2013). These exam-
ples illustrate that to understand the function of specific
PTPs in cancer, it is essential to identify their physiologi-
cal substrates and the relevant signaling pathways that
they regulate.
Our analysis established a positive correlation between
the overall breast cancer survival rate and the levels
of PTPN23 mRNA. Additionally, we detected lower ex-
pression of PTPN23 in several types of breast tumor com-
pared with adjacent normal tissue (Fig. 1). Our study also
showed that suppression of PTPN23 induced breast tu-
morigenesis in mice. The majority of tumors derived
from transplanted PTPN23-deficient CD cells in vivo
were typical basal-like breast cancers, adenosquamous
carcinomas, or anaplastic carcinomas (Fig. 1). Using the
Curtis model of 10 subtypes (Curtis et al. 2012), we as-
signed the effects of hemizygous or homozygous loss of
PTPN23 (deletion of chromosome 3p21.3) to IntClust10.
Breast cancer in this category was highly genomically
instable. Most tumors were basal-like, which is in agree-
ment with what we observed in our transplantation
model. In addition, using Lehmann’s study of TNBC
(Lehmann et al. 2011; Lehmann and Pietenpol 2014), we
assessed loss or suppression of PTPN23 as most likely to
lead to breast cancer of the MSL (mesenchymal stem-
like) subtype. This subtype is enriched for genes associat-
ed with growth and motility pathways and responds to
dasatinib, an inhibitor of SRC/ABL PTKs. In a parallel
xenograft model using a HER2-positive breast cancer
cell line, suppression of PTPN23 also facilitated BT474
xenograft outgrowth (Supplemental Fig. S4), suggesting
that PTPN23may exert a general tumor-suppressive func-
tion in different subsets of breast cancer. But what of its
mechanism of action?
Members of the PTP family are defined by the presence
of a conserved catalytic domain. In the 37 classical pTyr-
specific PTPs, we identified 10 sequencemotifs that serve
either structural or enzymatic functions (Andersen et al.
2001); within the PTPN23 gene, three of these motifs
diverge from the consensus, leading to suggestions that
PTPN23 may actually be a pseudophosphatase (Gingras
et al. 2009b). One study reported that the investigators
had failed to detect activity in the recombinant protein
using DiFMUP (6,8-difluoro-4-methylumbelliferyl phos-
phate, a small-molecule substrate that can be used to detect
phosphatase activity based on changes in fluorescence) and
various phosphatidylinositol phospholipids (Gingras et al.
2009b). It was also reported that the recombinant catalytic
domain of PTPN23 did not register activity against a panel
of 38 phosphopeptides (Barr et al. 2009). In contrast, the
Figure 7. Model to illustrate our proposedmechanism for breast
tumorigenesis induced by suppression of PTPN23 in vivo. In this
workingmodel, the suppression of PTPN23 impaired the dephos-
phorylation of FYN on Y420 in cancer cells. Enhanced autophos-
phorylation of the tyrosine in the activation loop of FYN
promoted kinase activity, which contributed to cell transforma-
tion in vivo, involving aberrant phosphorylation of substrates
such as β-catenin and disrupted regulation of downstream signal
cascades.
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active site Cys residue (and therefore, presumably, cata-
lytic function) was required for PTPN23 to suppress
RAS-mediated cell transformation (Cao et al. 1998). Sim-
ilarly, in our study, we identified FYN as a physiological
substrate of PTPN23, with dephosphorylation of Tyr420,
the activating autophosphorylation site, underlying its
tumor suppressor function in breast cancer models. The
deviations from the consensus sequence of active PTP
domains in PTPN23 include a substitution of His for
Tyr at the position of the Tyr residue that defines the
depth of the active site cleft, a substitution of Glu for
Asp at the position of the residue that serves as a general
acid/base in catalysis, and a substitution of Ser for Ala in
the PTP signature sequence that forms the base of the ac-
tive site cleft. Although these changes would be expected
to impair activity, it is not clear whether they would be
expected to inactivate the enzyme completely. In fact,
our data illustrate that although PTPN23 does display
intrinsic activity against FYN, the activity of a triple
mutant (H1223Y/E1357D/S1394A) to convert to the con-
sensus sequence was enhanced. By using the substrate-
trapping technology developed in the laboratory (Flint
et al. 1997), we demonstrated an interaction between
FYN and substrate-trapping mutant forms of PTPN23—
but not the wild-type form of the enzyme—that required
the presence of the Tyr420 autophosphorylation site in
FYN, which is indicative of an enzyme–substrate interac-
tion.The reason for the discrepancy between these various
studies is unclear; however, it is interesting to note paral-
lels with the study of other proteins that were originally
labeled pseudoenzymes. For example, within the kinome,
CASK (Mukherjee et al. 2008), the JH2 domain of JAK2
(Ungureanu et al. 2011), kinase suppressor of RAS (KSR)
(Brennan et al. 2011), and HER3 (Shi et al. 2010) were all
described initially as pseudokinases but are now recog-
nized as displaying intrinsic catalytic activity. This is
true also for other enzyme classes; for example, UTY, a
methyl lysyl demethylase (Walport et al. 2014). Thus, as
individual enzymes are studied in greater depth, new in-
sights are revealed, such as the identification of specific
substrates thatmay lead to reassessment of initial classifi-
cations of a protein as a pseudoenzyme based primarily on
sequence.
In this study,we identified FYNas a direct substrate and
downstream effector of the tumor suppressor function of
PTPN23 in breast tumorigenesis (Fig. 7). We validated
this novelmechanism in two xenograftmodels by demon-
strating that suppression of FYN function either with the
small-molecule SFK inhibitor AZD0530 or by genetic
deletion of FYN abrogated tumor formation caused by
loss of PTPN23 (Figs. 5, 6). FYN is one of the 11 members
of the extended SRC family of PTKs, which are the largest
nonreceptor kinase family in the human genome and act
as central mediators, interacting with multiple receptors
and transmembrane molecules to transmit extracellular
stimuli in different signaling pathways (Kim et al. 2009).
SRC, the first defined oncogene, has been implicated in
mediating effects of receptor tyrosine kinases such as
HER2 and EGFR in breast cancer (Tan et al. 2005).
Although somatic mutations in the SRC family of PTKs
are rare in cancer, their overexpression or aberrant activa-
tion has been implicated in oncogenesis andmetastasis of
several cancers, including breast cancer. It is interesting to
note thatmembers of the PTP family have the potential to
play an important role as both positive and negative regu-
lators of SFK activity. This is based on the regulation of
SFKs by their phosphorylation at two sites: an inhibitory
C-terminal site of phosphorylation by the inhibitory ki-
nase CSK and an activating site of autophosphorylation
(Okada 2012). Dephosphorylation of theC-terminal inhib-
itory phosphorylation site, with the accompanying activa-
tion of SFKs, is a major mechanism by which PTPs may
act positively to promote tyrosine phosphorylation-
dependent signaling. For example, CD45 (Mustelin et al.
1992), PTPα (Bhandari et al. 1998; Ponniah et al. 1999),
and LAR (Tsujikawa et al. 2002) have been reported to ac-
tivate FYN through dephosphorylation of the C-terminal
inhibitory tyrosine residue (Tyr531). In contrast, dephos-
phorylation of the activating autophosphorylation site
represents a mechanism for suppression of SFK activity.
For example, the striatal-enriched phosphatase (STEP)
has been shown to be a negative regulator of FYN activity
through direct dephosphorylation of the autophosphory-
lated tyrosine (Tyr420) (Nguyen et al. 2002; Xu et al.
2015). Also, it has been reported that DEP-1 may partially
function by inhibiting the activity of FYN to promote
migration and phagocytic activity of microglial cells in
the brain (Schneble et al. 2017). In contrast, PTPN23 is
expressed more broadly in fibroblasts and epithelial cells
of different organs (Gingras et al. 2009a). The mechanism
underlying the apparent specificity of PTPN23 for FYN in
this study remains to be defined. The basis for substrate
specificity among the PTPs is complex and may differ
from enzyme to enzyme. It seems to bemore complicated
than the situation in kinases, which recognize consensus
primary sequence motifs surrounding the cognate phos-
phorylation site. It is important to note that the activation
loops of the SFKs are highly conserved, indicating ele-
ments beyond the primary sequence that control PTP spe-
cificity. In fact, the expression pattern of a particular PTP
may determine in part its ability to function as a regulator
of SFKs in a particular cellular or tissue context.
FYN is a ubiquitously expressed SFK and acts as amajor
regulator of various signaling pathways that determine
cell proliferation, migration, and invasion, including T-
cell receptor (TCR) signaling and neuroplasticity. Overex-
pression of FYN results in anchorage-independent and
morphological transformation of NIH 3T3 cells (Kawa-
kami et al. 1988). In addition, FYN promotes breast
cancer metastasis via regulation of matrix rigidity at the
secondary (bone) site (Kostic et al. 2009), and elevated lev-
els of FYN have been reported in the epithelial-to-mesen-
chymal transition of breast cancer cells cocultured with
mesenchymal stem cells (Martin et al. 2010). Aberrant ex-
pression and activation of FYNhas also been implicated in
several malignancies, including glioblastoma, melanoma,
and prostate cancer (Huang et al. 2003; Lu et al. 2009;
Posadas et al. 2009; Saito et al. 2010). In breast cancer
patients, several studies have shown a strong associa-
tion of elevated expression/activation of FYN, usually
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accompanied by up-regulation of FAK and c-Met and poor
survival (Garcia et al. 2007; Charpin et al. 2009; Wang
et al. 2010), all of which reinforce the potential signifi-
cance of FYN as a therapeutic target.
Considering the critical function of SFKs in the regula-
tion of key pathways of cell survival and proliferation,
clinical trials are under way in breast cancer with SRC
kinase-directed small-molecule inhibitors (dasatinib and
bosutinib) in monotherapy and combination therapy
(Kim et al. 2009; Mayer and Krop 2010). The transplanta-
tion animal models used in our study have now revealed a
general tumor-suppressive function of PTPN23 in breast
tumorigenesis and that inactivation of this PTP was asso-
ciated with aberrant activation of FYN, which supports
the identification of FYN as a novel therapeutic target
for breast cancers defined by hemizygous or homozygous
loss of PTPN23. Therefore, the search for drug-like selec-
tive inhibitors of the kinase activity of FYN may provide
a new approach to treatment of breast tumors that feature
loss of PTPN23 function.
Materials and methods
Cell culture
We followed published conditions for culture of CD cells (Deug-
nier et al. 2006), BT474 cells (Lin et al. 2011), and TNBC cell lines
Cal51, MDA-MB-231, and MDA-MB-468 (Rajaram et al. 2013).
HEK293T cells were maintained in growth medium containing
high-glucose DMEM (Gibco, Invitrogen) supplied with 10% FBS
(Gibco, Invitrogen) and 1% penicillin–streptomycin (Gibco,
Invitrogen).
RNAi
For stable suppression ofmurine PTPN23 inComma 1D cells, we
expressed the pMLP retroviral vector with either of two shRNA
targeting sequences against Ptpn23 (Supplemental Table S1)
and sorted stable cell lines using GFP-based flow cytometry. De-
tailed protocols were described by Lin et al. (2011). For stable sup-
pression of human PTPN23 and expression of firefly luciferase in
BT474, we coexpressed pMLP retroviral vector with two shRNA
targeting sequences against PTPN23 (Supplemental Table S1)
and the pMSCV vector with a luciferase cassette. BT474 stable
cell lines were selected using puromycin and hygromycin. Specif-
ically, retroviral particles expressing shPTPN23were generated in
the 293T Phoenix cell ampho strain by cotransfecting pMLP,
pCLeco, and pVSVG at a ratio of 3:1:1. Retroviral particles
expressing firefly luciferase were generated following the same
protocols with the pMSCV vector. Twenty-four hours after
transfection, viral particles were harvested, filtered, and titered.
BT474 cells were then incubated with retroviral particles in the
presence of 8 µg/mL polybrene (Millipore). After 48 h, BT474 cells
were cultured in growth medium with 2 µg/mL puromycin
(Sigma) and 250 µg/mL hygromycin (Sigma) for dual selection.
The effectiveness of retroviral infection in both Comma 1D and
BT474 was confirmed by immunoblotting with the indicated
antibody.
CRISPR/CAS9 gene knockout
ForPtpn23 and/orFyn gene ablation inCal51 cells,we established
a Cal51 cell linewith stable expression of hSpcas9 (Cal51_CAS9).
We expressed a pLKO lentiviral vector with an hSpcas9 cassette
and selected the stable cell line using blasticidin. For CRISPR
knockout of PTPN23 in Cal51, we transfected Cal51_CAS9 with
a LRG lentiviral vector expressing sgRNA sequences against
PTPN23 and sorted stable cell lines using GFP-based flow cytom-
etry. Specifically, lentiviral particles expressing sgPTPN23 were
generated in HEK293T cells by cotransfecting sgRNA vector,
pPAX2, and pVSVG at a ratio of 4:3:2. Twenty-four hours after
transfection, viral particles were harvested, filtered, and titered.
Cal51_CAS9 cells were then incubated with lentiviral particles
in the presence of 8 µg/mL polybrene (Millipore). After 48 h,
Cal51 cells were sorted according to GFP expression followed
by single clone selection. For CRISPR knockout of FYN in
Cal51, we followed the same protocols with LRCh vector and
mCherry-based flow cytometry sorting. For double knockouts
of PTPN23 and FYN in Cal51, we cotransfected Cal51_CAS9
with both LRG and LRCh lentiviral vectors for sgRNA against
PTPN23 and FYN, respectively. Stable cell lines were sorted
using dual-color (GFP andmCherry) flow cytometry. The sgRNA
sequences used for PTPN23 and FYN knockout are listed
in Supplemental Table S1. The effectiveness of CRISPR gene
knockout was further confirmed by immunoblotting with the
indicated antibody.
Animal work
All study protocols involving mice were approved by the Institu-
tional Animal Care and Use Committee of Cold Spring Harbor
Laboratory and conducted in accordancewithNational Institutes
of Health guidelines for the care and use of animals. In the ortho-
topic transplantation model, CD cells were trypsinized, counted,
and resuspended at a concentration of 100,000 cells per 10 µL in
RPMI within two passages after sorting. Three-week-old BALB/c
mice (Charles River Laboratories) were anesthetized, and the
fourth (left) and ninth (right) inguinal mammary fat pads were
cleared of endogenous epitheliumby removing the tissuebetween
thenippleandthe lymphnodeaccordingtoestablishedprocedures
(Ehmann et al. 1987). Next, 100,000 cells in 10 µL RPMI were in-
jected into the epithelium-free fat pad, and the incisionwas closed
with sutures. Mice weremonitored by palpation twice a week for
tumoronset from1moaftermammaryepithelial cell inoculation.
Micewere euthanizedwhen tumors reached 1.5–2 cm in diameter
or 56 wk after transplantation. All tumors and mammary glands
wereharvested andweighedbefore theywere fixed for histological
analysis and frozen for future biochemical analysis.
In BT474 xenograft models, 1.5 × 106 luciferase-expressing
BT474 cells were injected orthotopically into mammary fat
pads of SCID-Beige mice (Tectonic Laboratory) in 15 µL of a 1:1
mixture with DMEM and growth factor-reduced Matrigel (BD
Biosciences). In each case, shPTPN23 BT474 cells were injected
into one side of the abdominal fat pad, and shCont cells were in-
jected contralaterally. Therefore, each mouse was injected with
tumor cells on one side and control cells on the other. In the pilot
study, animals were allowed to develop tumors. Tumor growth
was monitored periodically by injecting 100 µL of 15 mg/kg D-
luciferin (Gold Biotechnology) intraperitoneally and imaging the
animal using a Xenogen imager (Xenogen IVIS-200 optical in
vivo imaging system). Tumor volume (in cubic millimeters) was
measured with calipers before imaging (calculated volume =
[width ×width × length]/2). In the rescue study, animals injected
with BT474 cells (shCont and shPTPN23 #1058) were randomly
assigned into two groups to receive DMSO/saline (vehicle) or 25
mg/kg AZD0530 (LC Laboratories) treatment orally every third
day. In addition to caliper measurements, tumor growth was
monitored by bioluminescence imaging. Mice were euthanized
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when tumors reached 1.5–2 cm in diameter or at the end point of
the study. All tumors were harvested and weighed before they
were fixed for histological analysis and frozen for future bio-
chemical analysis. The same procedures were used for the
Cal51 xenograft model; 1.5 × 106 Cal51 cells were injected ortho-
topically into mammary fat pads of SCID-Beige mice (Tectonic
Laboratory), and tumor growth in the four cohorts of animals
was monitored as described above.
Histology
Paraffin-embedded tissues were sectioned and stained with H&E
or stored for further paraffin or fluorescence IHC. All slides were
digitally scanned with an Aperio ScanScope XT automated scan-
ning system. Images were shared in a Cold Spring Harbor Labora-
tory public database, and the pathological stage and histological
grade of CD-derived breast tumors were analyzed with the help
of J.E. Wilkinson.
Fluorescence microscopy
For GFP detection of dissected tissues from transplantation ani-
mals, tumors ormammary glandswere fixed in 4%paraformalde-
hyde overnight after dissection. Next, tissues were embedded in
3% agarose and cut into 50-µm-thick sections using a vibratome
(Leica, VT1000S). GFP fluorescence images were acquired using a
Zeiss LSM 510 microscope with a 40× objective.
Cell and tissue lysate preparation, immunoprecipitation, and
immunoblotting
Comma 1D, BT474, Cal51, or HEK293T cells were lysed in either
1% NP40 lysis buffer (20 mM HEPES at pH 7.5, 150 mM NaCl,
1%NP40, 50mMNaF, 1mMNa3VO4, 10% glycerol, protease in-
hibitor cocktail from Roche) or modified RIPA buffer (50 mM
Tris-Cl at pH 7.4, 150 mM NaCl, 1% NP40, 1% sodium deoxy-
cholate, 0.1% SDS, 50 mM NaF, 1 mM Na3VO4, 10% glycerol,
protease inhibitor cocktail from Roche) for 30 min at 4°C. Cell
debris was removed by centrifugation. For mammary glands
and tumors, extra connective tissue was carefully dissected
from harvested tissues. Tissue samples were ground into a pow-
der under liquid nitrogen and lysed for 30 min on ice in 1%
NP40 lysis buffer. The tissue lysates were cleared by centrifuga-
tion at 12,000g for 15 min at 4°C. Protein concentration was
determined by Bradford protein assay (Bio-Rad).
For immunoprecipitation, cell or tissue extracts were incubat-
edwith the indicated antibody for 4 h in a cold roomwith rotation
followed by further incubation for 1 h after addition of 1:1 protein
A/G agarose beads (GE Healthcare). Immunoprecipitates were
washed with lysis buffer three times before gel electrophoresis.
For immunoblotting, proteins were resolved by SDS-PAGE and
transferred onto nitrocellulose membranes. The membrane was
incubated overnight at 4°C with primary antibody followed by
incubation with the horseradish peroxidase-conjugated second-
ary antibody. Immunoreactive proteins were detected by chemi-
luminescence (Thermo Fisher). The primary antibodies used
for immunoprecipitation and immunoblotting were as follows:
PTPN23 (human, Proteintech; mouse, polyclonal antibody from
Dr. Pause, McGill University, Montreal, Canada); pTyr142 β-cat-
enin and FYN (Abcam); β-catenin, auto-pTyr SFK (pTyr416 SFK),
c-ter pTyr SFK (pTyr527 SFK), SRC, FER, c-MET, and YES (Cell
Signaling Technology); and β-actin (Sigma).
Site-directed mutagenesis
All point mutations were individually introduced into the coding
sequences of the specific target gene regardless of vectors by using
a QuickChange site-directed mutagenesis kit (Stratagene) to gen-
erate mutant forms of full-length PTPN23 (C1329S and E1357A),
the PTPN23 catalytic domain (C1329S, H1223Y, E1357D,
S1394A, and H1223Y/S1394A/E1357D), and full-length FYN
(Y420F and Y531F).
Recombinant protein purification and phosphatase activity assay
All pET-28a constructs with a PTPN23 catalytic domain-coding
cassette insert were introduced into the bacterial strain BL21-
RIL for recombinant protein production and purification. The
proteins were purified following published procedures (Lin et al.
2011). After purification, protein concentration was measured
by extinction coefficient at A280 (Nanodrop 1000, Thermo Fish-
er) and based on the calculated extinction coefficient. Proteins
were stored frozen in 30%glycerol-containing buffer for phospha-
tase activity assay. Plasmid expressing the FYN Y531F mutant
was transfected into Comma 1D cells for 24 h followed by immu-
noprecipitation from cell lysates with an antibody against FYN.
Each immunoprecipitate was split into equal aliquots and
incubated with purified PTPN23 and its various mutants (range
0–200 ng) for 30 min at 30°C. The in vitro dephosphorylation re-
action was terminated with Laemmli sample buffer, and proteins
were separated by SDS-PAGE. Substrate dephosphorylation was
visualized by immunoblotting.
Cell proliferation assay
CellTiter-Glo luminescence cell viability assay (Promega) was
used to evaluate the effect of ablating PTPN23 on proliferation
of CD or human breast cancer cells (BT474 and Cal51). In brief,
1000 cells per well were seeded in a 96-well plate and grown for
the indicated time intervals. CellTiter-Glo reagent was added to
each well and mixed for 15 min on an orbital shaker to induce
cell lysis, followed by luminescence reading. Results represent
mean ± SEM from three independent experiments.
IHC and TMA
Human breast cancer TMAs (TMA BC081116c and TMA
BR10011a) were purchased from US Biomax, Inc. Immunohisto-
chemical staining for PTPN23, pTyr142 β-catenin, β-catenin,
and auto-pTyr SFK (pY416 SFK) was performed in Histology
Shared Resource at Cold Spring Harbor Laboratory (DAB chromo-
gen kit, Vector Laboratories). Slides were digitally scanned with
the Aperio ScanScope software. For quantification of IHC stain-
ing, the Aperio cytoplasm analysis algorithm was used according
to themanual. For analysis, 10–15 areas containing only tumor or
adjacent normal epithelial cells were traced for analysis. Primary
antibodies used for IHC and TMA were as follows: PTPN23
(human, Proteintech;mouse, polyclonal antibody fromDr. Pause,
McGill University, Montreal, Canada), pTyr142 β-catenin
(Abcam), auto pTyr SFK (pTyr416 SFK, R&D Systems), and β-cat-
enin (Cell Signaling Technology).
Clinical data analysis for PTPN23 in breast cancer
For analysis of PTPN23 in breast cancer clinical samples, a data
set of 1069 breast cancer cases (BRCA) was extracted from
TCGA database (https://cancergenome.nih.gov); clinical follow-
up information is in Supplemental Table S2. All cases were divid-
ed into high and low PTPN23 subgroups based on the median
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PTPN23 mRNA expression value. Kaplan-Meier survival curves
for both the low and high PTPN23 subgroups were generated
using the survival package in R (https://cran.r-project.org/
package=survival). For analysis of PTPRG, we followed the
same protocols with the same data set of breast cancer cases.
Statistical significance was assessed by the log-rank test.
Statistics
The breast cancer clinical data were presented as Kaplan-Meier
survival curves, generated with the survival package in R, and
statistical comparison of the curves was based on the log-rank
test. All other charts were generated with GraphPad Prism
6.0 software. The median was chosen such that the two groups
(high and low) would have an equal number of patients and
thus that the statistics would not be driven by a minor (under-
powered) population. In the orthotopic transplantation model,
comparisons of Kaplan-Meier survival and tumor-free curves
were also based on the log-rank test. In xenograft models with
BT474 as well as Cal51 cells, statistical comparisons of animal
body weight and in vivo tumor volume between different cohorts
were based on the log-rank test. Statistical comparisons of ex vivo
tumor volume and tumor weight were based on the Mann-
Whitney test. A two-tailed Student’s t-test was also used for com-
parisons of data from in vitro cell proliferation assays as well
as IHC and TMA assays. Statistical significance was defined as
P < 0.05 (∗) and P < 0.01 (∗∗) for all tests.
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